RDAF position on the KVV / KLV revision

21 Nov, 2023

The revision of the Health Insurance Ordinance (KVV/OAMal) and the Health Benefits Ordinance (KLV/OPAS), presented by the Federal Council in September, will further deteriorate access to treatment and quality of care for rare disease patients in Switzerland. The specific needs of patients with rare diseases are still not fully reflected in the KVV and KLV.

The RDAF supports the improvements made to the system for reimbursement in individual cases, including the involvement of therapeutic experts in the benefit assessment, the obligation for insurers to justify negative decisions and the possibility to conduct joint assessments. However, the RDAF is of the opinion that the tool to be used by all insurers as of January 2024, the OLUtool, is not adapted to the specific characteristics of rare diseases and orphan drugs. Additionally, mandatory price cuts could delay access to treatment for patients with rare diseases, who are often facing a lack of therapeutic alternatives.

Read the RDAF full statement here.

The RDAF publishes the report from its workshop on post-marketing registries

The report from the RDAF multi-stakeholder workshop on post-marketing registries for rare diseases, which took place on 21 September 2023 in Basel, is now available. The workshop fostered an inclusive dialogue between academia, healthcare professionals, industry,...

RDAF hosts multi-stakeholder workshop on post-marketing registries

The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...